William Blair analyst Raju Prasad maintained a Buy rating on PTC Therapeutics (PTCT) yesterday. The company’s shares closed yesterday at $34.54.
According to TipRanks.com, Prasad is a 5-star analyst with an average return of 21.8% and a 60.0% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Logicbio Therapeutics Inc, and Audentes Therapeutics.
Currently, the analyst consensus on PTC Therapeutics is a Strong Buy with an average price target of $50.67, representing a 46.7% upside. In a report issued on February 22, RBC Capital also maintained a Buy rating on the stock with a $40 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $52.95 and a one-year low of $24.10. Currently, PTC Therapeutics has an average volume of 851.8K.
Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel medicines using its expertise in RNA biology. The company’s internally discovered pipeline addresses multiple therapeutic areas, including rare disorders and oncology.
